153 related articles for article (PubMed ID: 37969442)
21. The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells.
Bergamaschi A; Madak-Erdogan Z; Kim YJ; Choi YL; Lu H; Katzenellenbogen BS
Breast Cancer Res; 2014 Sep; 16(5):436. PubMed ID: 25213081
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma.
Xia JT; Wang H; Liang LJ; Peng BG; Wu ZF; Chen LZ; Xue L; Li Z; Li W
Pancreas; 2012 May; 41(4):629-35. PubMed ID: 22249132
[TBL] [Abstract][Full Text] [Related]
23. Expression, association with clinicopathological features and prognostic potential of CEP55, p-Akt, FoxM1 and MMP-2 in astrocytoma.
Nie S; Lou L; Wang J; Cui J; Wu W; Zhang Q; Liu Y; Su L; Chang Y; Guo W; Shen H; Xing L; Li Y
Oncol Lett; 2020 Aug; 20(2):1685-1694. PubMed ID: 32724411
[TBL] [Abstract][Full Text] [Related]
24. Transgenic expression of the forkhead box M1 transcription factor induces formation of lung tumors.
Wang IC; Meliton L; Tretiakova M; Costa RH; Kalinichenko VV; Kalin TV
Oncogene; 2008 Jul; 27(30):4137-49. PubMed ID: 18345025
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of forkhead box M1 and urokinase-type plasminogen activator in gastric cancer is associated with cancer progression and poor prognosis.
Ma J; Qi G; Xu J; Ni H; Xu W; Ru G; Zhao Z; Xu W; He X
Oncol Lett; 2017 Dec; 14(6):7288-7296. PubMed ID: 29344165
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of FOXM1 predicts poor prognosis and promotes cancer cell proliferation, migration and invasion in epithelial ovarian cancer.
Wen N; Wang Y; Wen L; Zhao SH; Ai ZH; Wang Y; Wu B; Lu HX; Yang H; Liu WC; Li Y
J Transl Med; 2014 May; 12():134. PubMed ID: 24885308
[TBL] [Abstract][Full Text] [Related]
27. [Forkhead Box M1 Regulates the Proliferation,Invasion,and Drug Resistance of Gastric Cancer Cells
Ge N; Jiang YY; Pan ZP; Wan J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Oct; 45(5):713-720. PubMed ID: 37927011
[TBL] [Abstract][Full Text] [Related]
28. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive bioinformatics analysis reveals the oncogenic role of FoxM1 and its impact on prognosis, immune microenvironment, and drug sensitivity in osteosarcoma.
Shi S; Wang Q; Du X
J Appl Genet; 2023 Dec; 64(4):779-796. PubMed ID: 37782449
[TBL] [Abstract][Full Text] [Related]
30. FOXM1: A potential indicator to predict lymphatic metastatic recurrence in stage IIA esophageal squamous cell carcinoma.
Xiao Z; Jia Y; Jiang W; Wang Z; Zhang Z; Gao Y
Thorac Cancer; 2018 Aug; 9(8):997-1004. PubMed ID: 29877046
[TBL] [Abstract][Full Text] [Related]
31. High expression of forkhead box M1 (FOXM1) is a poor prognostic biomarker in lung adenocarcinoma.
Xiao H; Jiang Z; Fu X; Kuang Y; Lin S; Cai Y; Zhang Q; Zheng F
Transl Cancer Res; 2020 Oct; 9(10):6331-6343. PubMed ID: 35117241
[TBL] [Abstract][Full Text] [Related]
32. [Clinical significance of FOXM1 and Gli-1 protein expression in high-grade ovarian serous carcinoma].
Zhang J; Li ZY; Duan XJ; Fan XM; Liu WN; Li YH
Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):904-908. PubMed ID: 27998466
[No Abstract] [Full Text] [Related]
33. [Expression of FoxM1 and BCRP in invasive breast carcinoma of no special type and its prognosis significance].
Liu Y; Liu YP; Liu JY; Yang HC; Wang ZD
Zhonghua Bing Li Xue Za Zhi; 2017 Jan; 46(1):30-33. PubMed ID: 28072973
[No Abstract] [Full Text] [Related]
34. Comprehensive analysis of FOXM1 immune infiltrates, m6a, glycolysis and ceRNA network in human hepatocellular carcinoma.
Xu Z; Pei C; Cheng H; Song K; Yang J; Li Y; He Y; Liang W; Liu B; Tan W; Li X; Pan X; Meng L
Front Immunol; 2023; 14():1138524. PubMed ID: 37234166
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Significance of Forkhead Box M1 (FOXM1) Expression and Antitumor Effect of FOXM1 Inhibition in Angiosarcoma.
Ito T; Kohashi K; Yamada Y; Iwasaki T; Maekawa A; Kuda M; Hoshina D; Abe R; Furue M; Oda Y
J Cancer; 2016; 7(7):823-30. PubMed ID: 27162541
[TBL] [Abstract][Full Text] [Related]
36. FOXM1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer.
Chu XY; Zhu ZM; Chen LB; Wang JH; Su QS; Yang JR; Lin Y; Xue LJ; Liu XB; Mo XB
Acta Histochem; 2012 Dec; 114(8):755-62. PubMed ID: 22326401
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of forkhead box M1 (FoxM1) expression and antitumour effect of FoxM1 inhibition in melanoma.
Ito T; Kohashi K; Yamada Y; Maekawa A; Kuda M; Furue M; Oda Y
Histopathology; 2016 Jul; 69(1):63-71. PubMed ID: 26619071
[TBL] [Abstract][Full Text] [Related]
38. Increased expression of forkhead box M1 protein is associated with poor prognosis in clear cell renal cell carcinoma.
Wu XR; Chen YH; Liu DM; Sha JJ; Xuan HQ; Bo JJ; Huang YR
Med Oncol; 2013 Mar; 30(1):346. PubMed ID: 23263830
[TBL] [Abstract][Full Text] [Related]
39. Expression of FOXM1 and related proteins in breast cancer molecular subtypes.
Lee JJ; Lee HJ; Son BH; Kim SB; Ahn JH; Ahn SD; Cho EY; Gong G
Int J Exp Pathol; 2016 Apr; 97(2):170-7. PubMed ID: 27277416
[TBL] [Abstract][Full Text] [Related]
40. Expression of FOXM1 and PLK1 predicts prognosis of patients with hepatocellular carcinoma.
Fan W; Ma H; Jin B
Oncol Lett; 2022 May; 23(5):146. PubMed ID: 35350587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
